Zirconium (89Zr) crefmirlimab berdoxam

Star0

DB19157InvestigationalProtein Based Therapies

Zirconium (89Zr) crefmirlimab berdoxam: Overview.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD8
Curator reviewed
Also known as: Iab22m2c (antibody fragment against the human cd8-antigen on cd8-positive t-cells, conjugated to the chelator desferrioxamine (df) and labeled with the radioisotope zirconium Zr-89) · ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM · Zirconium zr 89-df-iab22m2c · Zirconium Zr-89 crefmirlimab berdoxam · Zirconium Zr-89-desferrioxamine-iab22m2c
Code names: 89ZR-DF-IAB22M2C

Resolves to

Compound

UNIIJ6AJI0OZ1OCAS2377668-38-5

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Zirconium (89Zr) crefmirlimab berdoxam, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account